Rubius Therapeutics has torn up its strategy. After reviewing human data on its lead candidates, the cell therapy biotech concluded investment in its two clinical prospects “is no longer justified,” ...

Rubius Therapeutics’ plan to revive its red blood cell therapy research with a new approach has run out of time and money, and the biotech is now looking to strike a deal to salvage what’s left of the ...

In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...

Rubius Therapeutics, Inc. (RUBY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Rubius Therapeutics has pulled in another $100 million to fund the advance of its red blood cell therapies. The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the ...

Most cell therapies in development use a T cell or some other type of immune cell that’s engineered to perform a particular therapeutic task. Rubius Therapeutics makes its cell therapies from red ...

Enthusiasm in the immuno-oncology therapies being developed by Rubius Therapeutics has allowed the biotech to quickly raise $220 million, a large chunk of which it will invest in a cell therapy ...

Cell therapy is one of the big ideas in biotech. Entrepreneurs have become captivated by possibilities of engineering white blood cells so they can be re-infused into patients and fight cancer. One ...